Accessibility Menu
Avenue Therapeutics logo

Avenue Therapeutics(OTC) ATXI

Current Price$0.27
Market Cap$889.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-40%
1 Month-10%
Avenue Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.272026-07-22
Avenue Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.85%USD 0.262026-07-15
1 month-10%USD 0.302026-06-22
3 month-50.91%USD 0.552026-04-23
Year to date-60.31%USD 0.682025-12-31
1 year-40.01%USD 0.452025-07-22
3 year-99.68%USD 85.502023-07-21
5 year-99.99%USD 2,216.252021-07-23
Since inception-100%USD 9,281.272017-06-27

Avenue Therapeutics Financials at a Glance

Market Cap

$889.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.40M

Net Income (TTM)

-$1.75M

EPS (TTM)

-$0.54

P/E Ratio

-0.50

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$0.27

Volume

17,006

Open

$0.27

Previous Close

$0.27

Daily Range

$0.27 - $0.27

52-Week Range

$0.15 - $0.97

Estimated Earnings Date

Aug 10, 2026

ATXI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avenue Therapeutics

Avenue Therapeutics develops medicines for hospital patients with pain or neurological disorders. Its main products aim to help people after surgery or with epilepsy. The company focuses on treatments that hospitals and doctors use for urgent care.

Pain Relief and Brainy Stuff: Avenue’s Main Offerings

  • IV Tramadol: Injectable pain medicine for post-surgery patients; 0% of recurring revenue, as no product sales yet.
  • BAER-101: Experimental drug for epilepsy and panic disorders; 0% of recurring revenue, still in development.
  • AJ201 (Exited): Former drug for a rare muscle disease; generated 100% of Q2 2025 revenue from license termination.

Growth Spurts and Detours: Avenue’s Expansion Moves

  • Acquired BAER-101 through Baergic Bio, expanding into neurology.
  • Terminated AJ201 license with AnnJi Pharmaceutical in April 2025, shifting focus to core pipeline.
  • Secured exclusive U.S. rights for IV tramadol from Revogenex (date undisclosed).
  • Raised $2.1 million via equity sales in H1 2025; ATM facility now closed after Nasdaq delisting.
  • Finalized FDA agreement for IV tramadol Phase 3 study protocol in January 2024, pending new funding.

Why Avenue Is a Bit Different

Avenue targets hospital-based pain and neurological treatments, focusing on unmet needs. Its business model relies on licensing and partnerships, reducing early research risks. The company operates with minimal staff and leverages support from Fortress Biotech.

Five Things You Need to Know

  • Q2 2025 revenue was $1.4 million, up from $0 in Q2 2024.
  • Net income reached $335,000 in Q2 2025, up from a $7.2 million loss.
  • Operating expenses fell 61% to $1.1 million in Q2 2025.
  • Cash was $3.3 million as of June 30, 2025, up from $2.6 million.

Bottom Line

Avenue has shifted from broad drug development to focus on hospital pain and neurology. Its future depends on funding and successful product approvals.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

1

CEO

Alexandra MacLean, MD, MBA

Website

www.avenuetx.com

Headquarters

Bay Harbor Islands, FL 10036, US

ATXI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

-149.29%

Net Income Margin

-124.79%

Return on Equity

-65.83%

Return on Capital

-179.37%

Return on Assets

-70.99%

Earnings Yield

-2.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$889.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.29M

Volume

17.01K

Avg. Volume

2.50K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$2.10M

EBITDA

-$2.06M

Operating Cash Flow

-$1.09M

Capital Expenditure

$0.00

Free Cash Flow

-$1.09M

Cash & ST Invst.

$2.42M

Total Debt

$0.00

Avenue Therapeutics Performance Analysis

Avenue Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 1,404,000N/A
Avenue Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31N/A
Avenue Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -121.91-50.6%
20232023-12-31USD -73.48-39.7%
20242024-12-31USD -9.00-87.8%
20252025-12-31USD -0.93-89.7%
Avenue Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30117.7%
Q32025-09-30-290.9%
Q42025-12-31-4.8%
Q12026-03-314.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$889.60KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$889.60K

N/A

Employees

1

N/A

Net Income

-$695.00K

+62.5%

EBITDA

-$714.00K

+62.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.42M

-31.0%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-70.99%

N/A

Return on Invested Capital

-1.75%

N/A

Free Cash Flow

-$438.00K

+63.1%

Operating Cash Flow

-$438.00K

+63.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DRMADermata Therapeutics, Inc.
$1.26-1.56%
VRAXVirax Biolabs Group Limited
$3.64-6.19%
WINTWindtree Therapeutics, Inc.
$0.01+0.00%
CARMCarisma Therapeutics, Inc.
$0.00+7.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%
NOKNokia
$10.30-0.03%

Questions About ATXI

What is the current price of Avenue Therapeutics?

Avenue Therapeutics is trading at $0.27 per share.

What is the 52-week range for Avenue Therapeutics?

Over the past 52 weeks, Avenue Therapeutics has traded between $0.15 and $0.97.

How much debt does Avenue Therapeutics have?

As of the most recent reporting period, Avenue Therapeutics reported total debt of $0.00.

How much cash does Avenue Therapeutics have on hand?

Avenue Therapeutics reported $2.42M in cash and cash equivalents in its most recent financial results.

What is Avenue Therapeutics’s dividend yield?

Avenue Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services